0.509
-0.01 (-2.79%)
| Previous Close | 0.523 |
| Open | 0.508 |
| Volume | 639,147 |
| Avg. Volume (3M) | 11,701,525 |
| Market Cap | 22,495,932 |
| Price / Sales | 0.220 |
| Price / Book | 1.35 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -63.52% |
| Operating Margin (TTM) | -7.46% |
| Diluted EPS (TTM) | -1.28 |
| Quarterly Revenue Growth (YOY) | -11.20% |
| Total Debt/Equity (MRQ) | 300.69% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | 3.02 M |
| Levered Free Cash Flow (TTM) | 5.51 M |
| Return on Assets (TTM) | -2.38% |
| Return on Equity (TTM) | -138.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Harvard Bioscience, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 8.27% |
| % Held by Institutions | 69.66% |
| 52 Weeks Range | ||
| Median | 3.00 (489.62%) | |
| Total | 1 Not Rated | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 13 May 2025 | 3.00 (489.62%) | Not Rated | 0.370 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jun 2025 | Announcement | Harvard Bioscience Appoints John Duke to Board of Directors |
| 12 May 2025 | Announcement | Harvard Bioscience Announces First Quarter 2025 Financial Results |
| 05 May 2025 | Announcement | Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET |
| 10 Apr 2025 | Announcement | Harvard Bioscience Announces CFO Transition |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |